Drug General Information (ID: DDIDZ42SQV)
Drug Name			Sparfloxacin		Drug Info		Lopinavir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antibiotics				Anti-Hiv Agents
Structure

Mechanism of Sparfloxacin-Lopinavir Interaction (Severity Level: Major)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Sparfloxacin				Lopinavir
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Sparfloxacin and Lopinavir

Recommended Action
Management		Coadministration of sparfloxacin with other drugs that can prolong the QT interval is considered contraindicated.

References
1	Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
2	Jaillon P, Morganroth J, Brumpt I, Talbot G "Overview of electrocardiographic and cardiovascular safety data for sparfloxacin. Sparfloxacin Safety Group." J Antimicrob Chemother 37(suppl a) (1996): 161-7. [PMID: 8737135]
3	Thomas M, Maconochie JG, Fletcher E "The dilemma of the prolonged QT interval in early drug studies." Br J Clin Pharmacol 41 (1996): 77-81. [PMID: 8838432]